Clinical Trials Logo

Clinical Trial Summary

To assess and compare the performance of the HR HPV HC2® test (Qiagen/Digene) and the APTIMA® HPV Assay (Hologic) using LBC Specimens (ThinPrep® Pap Test) for the detection of HPV infection and high-grade CIN lesions in a screening population of women 30 years of age or older in Germany.


Clinical Trial Description

The study is conducted in the areas of Tuebingen, Freiburg and Saarbruecken in Germany. In total, 10.000 ThinPrep® LBC cervical samples were collected from June 2009 to May 2012. Liquid based cytology (LBC) was performed by a central laboratory in Saarbruecken. Human papilloma virus (HPV) testing with the HR HPV HC2® test and APTIMA® HPV Assay were performed at the Section of Experimental Virology, Institute of Medical Virology, University Clinic of Tuebingen, Germany (UKT). Within a follow-up phase women who tested positive in any test at baseline will be monitored over a period of 10 years. Study close out visit: In addition, approximately 5 years after baseline ThinPrep® LBC cervical samples will be collected from a random sample of 4000 study participants who tested triple negative at baseline for determination of the longitudinal negative predictive value (NPV) and HPV related disease after a 5 year period. Women who tested positive in any test will undergo colposcopy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02634190
Study type Observational
Source Hologic Deutschland GmbH
Contact
Status Completed
Phase
Start date June 2009
Completion date December 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04199078 - Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions. N/A
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02258659 - Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer Phase 2
Completed NCT02714114 - Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study) N/A
Completed NCT00303823 - Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia Phase 2
Not yet recruiting NCT05510830 - Diagnostic Cervical Conization for Persistent Infection or Integration of HPV N/A
Completed NCT04002154 - Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV N/A
Not yet recruiting NCT06123533 - Understanding Women's Values in Managing Human Papillomavirus (HPV)
Completed NCT04624568 - Papilocare®: Effects on Regression of Histologically Confirmed Cervical Intraepithelial Lesions 1 and Tolerance N/A
Completed NCT05694728 - A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine Phase 2
Completed NCT04391647 - Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
Recruiting NCT05439083 - Immunogenicity of 9-valent HPV Vaccine Phase 4
Completed NCT01539668 - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas Phase 0
Completed NCT01446198 - Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHERâ„¢ System N/A
Completed NCT01567813 - Post-Licensure Study of the Safety of GARDASILâ„¢ in Males (V501-070)
Completed NCT02811367 - The HPV Self-test as a Test of Cure in Madagascar N/A
Completed NCT02067507 - Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County N/A
Recruiting NCT01387997 - e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses N/A
Completed NCT00054041 - Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Phase 2
Active, not recruiting NCT01898494 - Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer Phase 2